Company intelligence / Profile preview

Fralex Therapeutics

Toronto, Ontario, Canadanewswire.ca ↗

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

Fralex Therapeutics developed a non-invasive medical device using Complex Neural Pulse (CNP) technology for the treatment of chronic pain conditions such as fibromyalgia and musculoskeletal pain. The company conducted pivotal clinical trials under FDA and Health Canada oversight and achieved CE marking for its PRIMA system in Europe. The RELIEF trial was a randomized controlled study targeting chronic pain associated with fibromyalgia. The company was acquired by Baylis Medical Company Inc.

Therapeutic areas: Rheumatology
Modalities: DeviceNon-pharmacological therapyNeuromodulation device (Complex Neural Pulse)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Fralex Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fralex Therapeutics.

Explore the full profile